Salles, Gilles
Chen, Jenny M. H. http://orcid.org/0000-0002-0575-3699
Zhang, Ina
Kerbauy, Fabio
Wu, James J.
Wade, Sally W.
Nunes, Ana
Feng, Chaoling
Kloos, Ioana
Peng, Weimin
Snider, Julia T.
Maciel, Dylan
Chan, Keith
Keeping, Sam
Shah, Bijal
Funding for this research was provided by:
Kite Pharma
Article History
Received: 22 December 2023
Accepted: 12 February 2024
First Online: 18 March 2024
Declarations
:
: Gilles Salles has received consulting fees from Abbvie, Celgene/BMS, Epizyme, Genmab, Incyte, Janssen, Kite, a Gilead Company, Loxo, Milteniy, Molecular Partners, Morphosys, Nordic Nanovector, Novartis, Rapt, and Takeda; has received payment or honoraria for speaking in symposium from Bayer, Epizyme, and Regeneron; has participated on a Data Safety Monitoring board or Advisory Board for Beigene; and has stock or stock options from Owkin. Jenny M.H. Chen, Ina Zhang, Dylan Maciel, Keith Chan, and Sam Keeping are employees of PRECISIONheor, funded by Kite, a Gilead Company for this study. Fabio Kerbauy declares no competing interests. James J. Wu is an employee of Kite, a Gilead Company; has received honoraria from the Patient-Centered Outcomes Research Institute (PCORI), both as a member of the Rare Disease Advisory Panel, and as a grants reviewer for the Improving Methods Program; has received travel/meeting support from Kite, a Gilead Company, and Amgen; owns stock in Gilead Sciences, Amgen, Abbott, AbbVie, Pfizer, Roche, Curis, Avid Biosciences, Evofem, Lensar, VBI Vaccines, and Viracta Therapeutics. Sally W. Wade has received consulting fees from Kite, a Gilead Company, Abbvie, and Johnson & Johnson. Fabio R. Kerbauy declares no competing interests. Ana Nunes is an employee of Gilead Sciences Europe; own stocks in Gilead Sciences and Amgen; and has received support for attending meetings and/or travel from Kite, a Gilead Company. Chaoling Feng is an employee of Kite, A Gilead Company; own stocks in Gilead Sciences, Boston Scientific, and has received support for attending meetings and/or travel from Kite, a Gilead Company. Ioana Kloos is an employee of Kite, A Gilead Company; own stocks in Gilead Sciences; and has been compensated for a leadership role (such as officer or member of a board of directors) for Kite, A Gilead Company. Weimin Peng is an employee of Kite, a Gilead Company; and owns stock in Gilead Sciences. Julia T. Snider is an employee of Kite, a Gilead Company; owns stock in Gilead Sciences. Bijal Shah has received consultant and education fees from Amgen, Pfizer, Novartis, BMS/Celgene/Juno, Kite, a Gilead company, Precision Biosciences, Jazz, Beigene, Adaptive, Century Therapeutics, and Autolus; and clinical trial grants from Kite, a Gilead company, Jazz, and Servier.
: Results presented in this article are based on a retrospective analysis of data from published studies, and therefore no institutional board review was required. Review boards at participating institutions approved the ZUMA-2 and BRUIN trials.